How to Buy Abcellera Biologics Stock
Abcellera Biologics Inc
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs.
Abcellera Biologics stock last closed at $2.45, up 1.24% from the previous day, and has decreased 38.9% in one year. It has overperformed other stocks in the Biotechnology industry by 0.39 percentage points. Abcellera Biologics stock is currently +29.56% from its 52-week low of $1.89, and -43.55% from its 52-week high of $4.34.
There are currently 297.99M shares of ABCL outstanding. The market value of ABCL is $730.07M. In the last 24 hours, 4.38M ABCL shares were traded.
How to Buy Abcellera Biologics Stock
Not sure how to invest in Abcellera Biologics stock? Here's how.
- Choose where to buy Abcellera Biologics stock: You need to choose an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you figure out where to buy Abcellera Biologics stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Pick your payment method and add your information.
- Research Abcellera Biologics stock: The Abcellera Biologics ticker symbol is ABCL. Is Abcellera Biologics stock a good investment? Should you buy shares of ABCL? How do ABCL's underlying business fundamentals look? Do top analysts think Abcellera Biologics is a good buy? Why has ABCL's stock price moved recently? (Hint: Our stock market analysis tools can help you decide if ABCL is a good stock to buy).
- Place your ABCL purchase: Decide if you will purchase ABCL shares at the current market price or use a limit order to buy ABCL stock at a particular price.
- Watch your ABCL position: Create a watchlist to watch your position in Abcellera Biologics shares.
Step 1: Choose where to buy Abcellera Biologics stock
You will need an online brokerage account to access the NASDAQ market and buy ABCL stock.
Our recommended brokerage: eToro
We believe that eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world financial markets: From Technology to Utilities, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro boasts a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've picked the right brokerage, you need to fill out some personal information so you can invest in ABCL today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to create a new trading account.
- Send your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have created your account on stock market app, you need to deposit funds:
Watch the video below if you need help depositing funds into your new investment account.
Step 4: Research Abcellera Biologics stock
After you have decided on the best place to buy Abcellera Biologics stock, it's absolutely critical to evaluate their stock before you buy, so you can understand the risk as well as the upside.
Abcellera Biologics quick stats
Fundamentals of Abcellera Biologics
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on ABCL's stock page.
Is ABCL stock properly valued?
You can use many financial metrics, analyses, models, and charts to gauge ABCL's true value.
Using relative valuations metrics:
- ABCL may be undervalued based on its P/B ratio of 0.69x, relative to Biotechnology industry P/B ratio of 4.04x
You can do more valuation analysis on ABCL's stock here.
Is ABCL a healthy company?
Passed Health Checks:
- There are more short-term assets than short-term liabilities on the ABCL balance sheet.
- Total ABCL debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the ABCL balance sheet.
- ABCL has $650.61M in cash and short term investments. This is sufficient to cover its annual cash burn of $186.95M.
- ABCL has cash burn of 186952000. It has enough cash and short-term investments to cover this for at least one year.
- ABCL has a low debt to equity ratio of 0.29.
Failed Health Checks:
- ABCL profit margin has gone down from -385% to -564.8% in the past year.
Do analysts think it's a good time to buy ABCL stock
Out of 2 Equities analysts who give ratings on ABCL, the consensus analyst rating on Abcellera Biologics is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are saying on the Abcellera Biologics stock forecast page.
ABCL Momentum
ABCL Growth Numbers
Last year, ABCL revenue was $28.83M. Over the past five year, ABCL's revenue has increased by 19.95% per year. This was slower than the Biotechnology industry average of 44.31%.
Learn more about ABCL's earnings and revenue performance here.
Latest Insiders Trades at ABCL
Over the last 12 months, executives and large shareholders at ABCL have bought more shares than they have sold.
Thermopylae Holdings Ltd, 10% Owner of ABCL, was the latest ABCL insider to buy. They bought $742,242.96 worth of ABCL shares on Mar 11, 2025.
Learn more about who owns ABCL shares here.
Can I rely on ABCL as an income stream?
No, Abcellera Biologics doesn't provide an income stream by paying out dividends.
What do other traders have to say about ABCL?
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Place your ABCL purchase
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually the easiest way to buy. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific price, place a limit order.
Hit the Open button and your broker will execute the order.
If you need additional help investing in stocks on eToro, click the helpful video below:
Step 6: Watch your ABCL position
Now that you own some ABCL shares, you'll want to stay up-to-date on your new shares.
Start a watchlist to track your ABCL stock.
ABCL Feed
How to Buy Stock in Abcellera Biologics
To summarize, here are the 6 steps you need to take to buy Abcellera Biologics stock right now:
- Choose where to buy Abcellera Biologics stock
- Create a brokerage account
- Put funds into your brokerage account
- Research Abcellera Biologics stock
- Place your ABCL purchase
- Watch your ABCL position
If you are looking for a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get updates on your new investment in Abcellera Biologics, hit the button below to create your watchlist.
More "How To" Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.